Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Long-Term Deferred Tax (2016 - 2022)

Corvus Pharmaceuticals' Long-Term Deferred Tax history spans 4 years, with the latest figure at $77.0 million for Q4 2022.

  • Quarterly Long-Term Deferred Tax changed N/A to $77.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $77.0 million through Dec 2022, changed N/A year-over-year, with the annual reading at $77.0 million for FY2022, N/A changed from the prior year.
  • Long-Term Deferred Tax came in at $77.0 million for Q4 2022, up from $56.1 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $77.0 million in Q4 2022 to a low of $56.1 million in Q4 2020.